103 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
15 Mar 19
Other Events
9:56pm
Exhibit 99.1
Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial … for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has recommended the continuation of the Company’s Phase III
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
10 Jan 20
Regulation FD Disclosure
5:16pm
with established decades-long safety profile Orphan asset in Phase III Study for Prader-Willi syndrome Phase III enrollment complete. Topline data 1H 2020 … ):e0221615
| © 2020 Soleno Therapeutics DCCR Safety Consistent with Long History of Safe Use of Diazoxide Safety profile of diazoxide in chronic use
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
15 Nov 18
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018
4:02pm
presented clinical data supporting the safety and efficacy of DCCR in PWS at both the European Society of Paediatric Endocrinology and Foundation … activated U.S. trial sites. Additional sites are being activated and resources being deployed to ensure timelines are met
Safety consistent with known
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
18 Mar 19
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
4:37pm
in our9-month open-label safety extension study, C602. Most recently, the Data Safety Monitoring Board (DSMB), the independent group of experts monitoring … the safety of the DESTINY PWS study, recommended the continuation of the study without modification, further supporting DCCR’s safety profile We look
8-K
EX-99.1
rhrnap s33kp4yoj
8 Jun 20
Regulation FD Disclosure
5:04pm
424B5
qzob sh9an
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.2
n5xpo4v80tl
8 Jun 20
Regulation FD Disclosure
5:04pm
8-K
EX-99.1
rrlnjro0ps2
10 Jul 23
Regulation FD Disclosure
4:06pm
424B5
1znregbr4 pul
22 Oct 19
Prospectus supplement for primary offering
4:24pm
424B5
lbsw99 qp28r2rj
27 Sep 23
Prospectus supplement for primary offering
5:26pm
424B5
087kpt61
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
afmjd65wzlfq67pnqs9i
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
m13hftl9piyv3n0pp
25 Oct 19
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
hz2d4r xfpxp6euodhb
13 May 19
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results
8:31am